Author

Salome Funes

Observed name: Funes, Salome

Institution: Apellis Pharmaceuticals (United States)

Observed institutions: University of Massachusetts Chan Medical School, Universidad de Las Américas, Apellis Pharmaceuticals (United States)

ORCID: 0000-0001-6531-4279

Observed ORCID: 0000-0001-6531-4279

OpenAlex ID: A5028224312

A reference human induced pluripotent stem cell line for large-scale collaborative studies

2022 · Caroline B. Pantazis, Andrian Yang, et al. · Cell stem cell · 347

ALS-linked PFN1 variants exhibit loss and gain of functions in the context of formin-induced actin polymerization

2021 · Eric J. Schmidt, Salome Funes, et al. · Proceedings of the National Academy of Sciences · 38

Expression of ALS-PFN1 impairs vesicular degradation in iPSC-derived microglia

2024 · Salome Funes, Jonathan Jung, et al. · Nature Communications · 28

Quantitative proteomics identifies proteins that resist translational repression and become dysregulated in ALS-FUS

2019 · Desiree M Baron, Tyler Matheny, et al. · Human Molecular Genetics · 22

Human Microglia-like Cells: Differentiation from Induced Pluripotent Stem Cells and In Vitro Live-cell Phagocytosis Assay using Human Synaptosomes

2022 · Salome Funes, Daryl A. Bosco · Journal of Visualized Experiments · 5

Complement meets Tau: Exploring the effects of a novel C3‐targeting siRNA in a Tauopathy mouse model

2025 · Maria‐Tzousi Papavergi, Salome Funes, et al. · Alzheimer s & Dementia

Leptin Receptor ( OBR ) Resistance On Immune Cells From People With Obesity

2015 · Salome Funes, Stephanie Santander, et al. · The FASEB Journal

Works count: 8

Citation count: 440

H-index: 5

I10-index: 4